Chapter 7:

Bibliography


60. Diagnosis and management of epilepsy in adults. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); April 2003.


67. Empson RM, Jefferys JG, Ca\textsuperscript{2+} entry through L-type Ca\textsuperscript{2+} channels helps terminate epileptiform activity by activation of a Ca\textsuperscript{2+} dependent afterhyperpolarisation in hippocampal CA3. Neuroscience. 2001;102(2):297-306.


82. Freiman TM, Kukolja J, Heinemeyer J, et al. Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin:
involvement of K+-ATP channels. Naunyn Schmiedebergs Arch Pharmacol.  
2001 May;363(5):537-42.
83. Gale K, Iadarola MJ, Seizure protection and increased nerve-terminal GABA:  
delayed effects of GABA transaminase inhibition. Science. 1980 Apr  
18;208(4441):288-91.
84. Gamble C, Williamson PR, Chadwick DW, et al., A meta-analysis of individual  
patient responses to lamotrigine or carbamazepine monotherapy. Neurology.  
2006 May 9;66(9):1310-7.
86. George LM, Anne EH, Robert PK, et al., Lamotrigine with patients with juvenile  
myoclonic epilepsy following prior treatment with valproate: results of an  
34.
89. Gibbs J, Appleton RE, Rosenbloom L, et al., Lamotrigine for intractable  
childhood epilepsy: a preliminary communication. Dev Med Child Neurol.  
90. Gibbs JW; Sombati S, DeLorenzo RJ, et al., Cellular actions of topiramate:  
blockade of kainate-evoked inward currents in cultured hippocampal neurons.  
91. Giuseppe F, Claudio DS, Giovanni M, Stevens-Johnson syndrome associated  
with single high dose of lamotrigine in a patient taking valproate. Dermatology  
93. Gomora JC, Daud AN, Weiergraber M, et al., Block of cloned human T-type  
calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001  
Nov;60(5):1121-32.
94. Graham JL, Smith SE, Chapman AG, et al., Effect of lamotrigine on  
microdialysate amino acid concentration in the striatum after focal cerebral  
95. Guidance for industry: bioavailability and bioequivalence studies for orally  
administered drug products - general considerations, CDER, Food and Drug  
Administration USA, March 2003.


114. In-vitro/In-vivo correlation for extended-release oral dosage forms, stimuli to the revision process. The United States Pharmacopeial Convention, Inc., 1988:4160;


122. Kakemi K, Absorption and excretion of chloramphenicol, symposium on drug absorption, metabolism and excretion, Paper B-IV, preprints of papers,
Bibliography

scientific section of the american pharmaceutical association, Las Vegas. **1962.**


188. PMA’s Joint Committee on bioavailability, the role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. Pharm. Technol. 1985;9:62-66.


Bibliography


Bibliography

249. Toufic AF, Anne EH, Alain V, et al., Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy & Behavior. 2004;5:532-38.


